Blog

The latest thoughts from Medicines Law & Policy partners.

The new IP strategy of war-torn Ukraine should prioritise public health and national security

Russia’s full-scale assault on Ukraine continues for the third year. The Russian occupation forces have already killed tens of thousands of civilians, including children. They have...

Wrapping up 2025: A tumultuous year for global public health law & policy

The end of 2025, a tumultuous year for global public health, is here, and it’s time for the usually highly biased Medicines Law &...

A better way to solve a crisis: A new mechanism for incentivising R&D on...

Antimicrobial resistance is the ‘silent’ pandemic: Globally, it costs 5 million lives a year, and is set to rise to more than 8 million...

Pharmaceutical Accountability Foundation is taking AbbVie to court over excessive pricing of Humira –...

On 21 February, the Dutch Pharmaceutical Accountability Foundation (PAF) took the bold step to take AbbVie to court, claiming the company’s pricing policy had...

2018 Round-up of Noteworthy Medicines Law and Policy Events

We are reaching the end of 2018: Time for our end-of-the-year roundup of some significant developments in medicines law and policy. January The Chilean parliament started...

The Urgency of Compulsory Licensing Provision for Transfer of Technology in the Pandemic Treaty:...

Guest blog by Ronald Eberhard The Intergovernmental Negotiating Body, established by the World Health Assembly, aims to draft a global pandemic prevention, preparedness, and response...

Wrapping up 2023 with some noteworthy medicines, law and policy developments

Welcome to our 2023 end-of-the-year blog, our annual and highly-biased run-through of notable access to medicines events of the year that is about to...

Dutch health insurance company Menzis takes AstraZeneca to court over patent evergreening

Today health insurance company Menzis announced  that it is taking the pharmaceutical company AstraZeneca to court over the pricing of Seroquel, a medicine...

Generic versions of a lifesaving cystic fibrosis treatment will save patients $360,000 a year...

Generic versions of a cystic fibrosis treatment will now be available at $6,375 per child, per year under a new scheme – offering hope...

WIPO and pharma industry launch global medicines patent database

On 25 September, the World Intellectual Property Organisation (WIPO) in collaboration with the International Federation of Pharmaceutical Manufacturers & Associations (IFPMA) launched the Patent...